Dr. Anju Samy has over 15 years of extensive experience in the pharmaceutical industry leading global regulatory strategy and execution for several programs in both rare and non-rare diseases across several therapeutic areas involving various modalities. At Horizon Therapeutics (acquired by Amgen Inc), she led multiple rare disease expedited pathway Phase 3 programs resulting in submissions and approvals of UPLIZNA® (inebilizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-Related Disease (IgG4-RD) and Myasthenia Gravis (MG) across the globe to the U.S Food and Drug Administration, European Medicines Agency, rest of world markets and Health Canada.
Dr. Samy is a registered pharmacist in the states of Indiana and Illinois. Prior to joining the industry, Dr. Samy was a clinical staff pharmacist in Northwest Indiana. Dr. Samy holds a Ph.D. in pharmacology and pharmaceutical sciences from the University of Missouri-Kansas City as well as a bachelor’s degree in pharmacy from University of Mumbai.